



## How To Order Pleximark™ Tx

**Web:** Check ordering information under –  
<http://www.plexision.com>

**Phone:** 1.855.753.9474 or 1.855.PLEXISION

**Fax:** 1.412.224.2776

### Mailing Address:

Plexision, Inc.  
4424 Penn Avenue, # 202,  
Medical Building,  
Pittsburg, PA, 15224-1338.

## Insurance Coverage

Plexision will bill the patient's insurance plan and work directly with the insurer for payment.

## Patient Assistance Program

Plexision will assist with the cost of Pleximark™ Tx, if there is no insurance coverage. For additional information, call 1.855.753.9474 or email [info@plexision.com](mailto:info@plexision.com).

## References

1. US Patent 8759016
2. Am J Transplant. 2009; 9(1): 179-913
3. Surgery. 2009; 146(2): 166-73
4. Pediatr Transplant, 2012; 16(0): 83-91
5. CLIA ID: 39D2042664
6. Transplantation, 2011. 92(4): 433-8



# Pleximark™ Tx

**Assessing the likelihood of renal transplant rejection**

## Description

Pleximark™Tx is a patented<sup>1</sup> blood test to assess the likelihood of acute cellular rejection after renal transplantation.\*

## Purpose

Knowledge about rejection can be combined with available clinical data to plan additional treatment for your patient.

## Rationale

- § Renal transplant rejection is usually suspected because of elevated serum creatinine. Elevated creatinine is also seen with infection and mechanical blockage. A “for cause” biopsy is needed to confirm rejection. Roughly half of “for cause” biopsies do not show rejection.
- § Rejection can also occur without affecting serum creatinine, especially if immunosuppression is suboptimal. Surveillance biopsies are performed at predetermined intervals to detect ‘silent’ rejection and assess immunosuppression.
- § The Pleximark blood test measures the likelihood of rejection. This knowledge can be combined with clinical information to develop a treatment plan. Benefits include:
  - improving long-term management with serial monitoring,
  - enhancing the diagnostic yield of “for cause” biopsies,
  - optimizing the frequency of surveillance biopsies.

## Intended Use

To assess the likelihood of acute cellular rejection after renal transplantation.

## Procedure

- § Pleximark™Tx is a functional cell-based blood test, which measures the immune response of recipient lymphocytes to donor lymphocytes in cell culture.
- § The test requires whole blood in sodium heparin tubes to be shipped at ambient temperature for overnight delivery to Plexision’s laboratory. Seven-10 ml whole blood are needed from adults, and 3-5 ml are needed from children.
- § Recipient T-cytotoxic memory cells, which express the inflammatory marker, CD40 ligand or CD154 are measured with flow cytometry.
- § Results are expressed as an index of rejection, which is a measure of the likelihood of rejection.
- § Results are reported the day after the blood sample is received at the laboratory, and within two days of obtaining the blood sample from the patient.
- § The technology underlying the Pleximark™Tx test has been evaluated in over 200 children with liver or intestine transplantation and adults with renal transplantation.<sup>2-4</sup>

## Performance

The Pleximark™Tx test is performed in Plexision's CLIA-approved<sup>5</sup> laboratory, and

- Has been developed in relationship to “for cause” biopsies in renal transplant recipients. Identifies renal transplant recipients experiencing rejection with sensitivity of 88% and specificity of 86%<sup>6</sup>.
- Identifies renal transplant recipients experiencing rejection with sensitivity of 88% and specificity of 86%<sup>6</sup>.
- Requires whole blood shipped at ambient temperature 3-5ml for children and 7-10 ml in adults

This knowledge can be combined with other clinical information to develop a treatment plan.